Pure Global

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients - Trial NCT05957380

Access comprehensive clinical trial information for NCT05957380 through Pure Global AI's free database. This Phase 4 trial is sponsored by Dong-A ST Co., Ltd. and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 108 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05957380
Phase 4
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05957380
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Study Focus

Hepatitis B

DA-2803

Interventional

drug

Sponsor & Location

Dong-A ST Co., Ltd.

Seoul, South Korea

Timeline & Enrollment

Phase 4

Mar 20, 2023

Nov 30, 2024

108 participants

Primary Outcome

HBV DNA(log10 IU/mL) change

Summary

This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical
 study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects

ICD-10 Classifications

Acute hepatitis B
Acute hepatitis B without delta-agent and without hepatic coma
Acute delta-(super)infection in chronic hepatitis B
Chronic viral hepatitis B without delta-agent
Chronic viral hepatitis B without delta-agent : other and unspecified phase

Data Source

ClinicalTrials.gov

NCT05957380

Non-Device Trial